Key result
Trained immunity drives atherosclerosis via epigenetic and metabolic reprogramming, highlighting a novel therapeutic target.
Atherosclerosis is characterized by incessant inflammation in the arterial wall in which monocytes and macrophages play a crucial role. During the past few years, it has been reported that cells from the innate immune system can develop a long-lasting proinflammatory phenotype after brief stimulation not only with microbial products but also endogenous atherogenic stimuli. This persistent hyperactivation of the innate immune system is termed trained immunity and can contribute to the pathophysiology of atherosclerosis. Trained immunity is mediated via epigenetic and metabolic reprogramming and occurs both in mature innate immune cells as well as their bone marrow progenitors. In addition to monocytes, other innate immune and nonimmune cells involved in different stages of atherosclerosis can develop comparable memory characteristics. This mechanism provides exciting novel pharmacological targets that can be used to prevent or treat cardiovascular diseases.
No takes yet. Share an insight, caveat, or question.
Flores-Gomez et al. (2020) conducted a review in Atherosclerotic Cardiovascular Disease. Trained immunity was evaluated. Trained immunity, mediated via epigenetic and metabolic reprogramming, contributes to the pathophysiology of atherosclerosis and represents a novel pharmacological target.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: